Tg Therapeutics Inc Quick Ratio (TGTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Tg Therapeutics Inc   (NASDAQ: TGTX)

Tg Therapeutics Inc 's Quick Ratio

TGTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Tg Therapeutics Inc 's Cash & cash equivalent grew by 57.78 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Tg Therapeutics Inc 's Quick Ratio to 3.02, Quick Ratio remained below Tg Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 235 other companies have achieved higher Quick Ratio than Tg Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1198, from total ranking in the first quarter 2026 at 2536.

Explain Quick Ratio?
How much Cash & cash equivalents TGTX´s has?
What are TGTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TGTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 56.2 % 16.79 % 69.57 % 25.33 % 58.18 %
Y / Y Cash & cash equivalent Change 222.26 % 86.23 % -54.35 % -61.42 % 15.93 %
Quick Ratio MRQ 3.02 2.75 0.92 0.84 1.47
TGTX's Total Ranking # 1198 # 2536 # 2471 # 1910 # 1777
Seq. Current Liabilities Change 43.5 % 21.69 % -1.95 % -8.77 % 7.29 %
Seq. Cash & cash equivalent Change 57.78 % 262.35 % 7.89 % -47.76 % -8.82 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 236
Healthcare Sector # 404
Overall Market # 1115


Quick Ratio Statistics
High Average Low
26.9 5.53 0.84
(Mar 31 2014)   (Sep 30 2025)




Financial Statements
Tg Therapeutics Inc 's Current Liabilities $ 268 Millions Visit TGTX's Balance sheet
Tg Therapeutics Inc 's Cash & cash equivalent $ 812 Millions Visit TGTX's Balance sheet
Source of TGTX's Sales Visit TGTX's Sales by Geography


Cumulative Tg Therapeutics Inc 's Quick Ratio

TGTX's Quick Ratio for the trailling 12 Months

TGTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 39.84 % 38.15 % 51.52 % 49.69 % 71.35 %
Y / Y Cash & cash equivalent TTM Growth 35.55 % -9.23 % -25.5 % -1.2 % 35.55 %
Quick Ratio TTM 2.09 1.55 1.25 1.67 2.15
Total Ranking TTM # 1220 # 2007 # 1216 # 1026 # 992
Seq. Current Liabilities TTM Growth 14.43 % 4.19 % 10.88 % 5.79 % 13.05 %
Seq. Cash & cash equivalent TTM Growth 53.83 % 29.71 % -17.41 % -17.75 % 3.02 %

Quick ratio ranking by company, industry and sector >> Back to TGTX Financial Strength Comparisons >> Go to Compare TGTX Quick Ratio to its Competitors

On the trailing twelve months basis TGTX Cash & cash equivalent more than doubled by 222.26 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Tg Therapeutics Inc 's Quick Ratio to 2.09, Quick Ratio remained below TGTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Tg Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2006.

Explain Quick Ratio?
How much Cash & cash equivalents TGTX´s has?
What are TGTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 885
Within the Market # 1198


trailing twelve months Quick Ratio Statistics
High Average Low
10.69 3.92 0.64
(Jun 30 2014)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Cytomx Therapeutics Inc   8.29 $ 330.280  Millions$ 39.861  Millions
Grace Therapeutics Inc  8.24 $ 13.756  Millions$ 1.669  Millions
Talphera Inc   7.98 $ 33.410  Millions$ 4.188  Millions
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions

Date modified: 2026-09-09T22:26:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.